Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × Advanced Cancers × Clear all

Phase

Phase 1 2 Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 374 Carcinoma, Non-Small-Cell Lung 248 Prostatic Neoplasms 186 Neoplasms 178 Neoplasm Metastasis 168 Melanoma 144 Colorectal Neoplasms 138 Multiple Myeloma 132 Leukemia, Myeloid, Acute 132 Lung Neoplasms 115 Leukemia 115 Lymphoma 106 Pancreatic Neoplasms 101 Recurrence 98 Leukemia, Lymphocytic, Chronic, B-Cell 97 Lymphoma, Non-Hodgkin 96 Carcinoma, Renal Cell 95 Ovarian Neoplasms 94 Myelodysplastic Syndromes 83 Brain Neoplasms 82 Precursor Cell Lymphoblastic Leukemia-Lymphoma 76 Lymphoma, Follicular 76 Glioblastoma 76 Lymphoma, Large B-Cell, Diffuse 73 Carcinoma, Hepatocellular 71 Head and Neck Neoplasms 68 Squamous Cell Carcinoma of Head and Neck 67 Urinary Bladder Neoplasms 54 Stomach Neoplasms 53 Hodgkin Disease 53

Interventions

ridaforolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00836927 2019-02-18

MK-8669-038

Merck Sharp & Dohme LLC

Phase 2 Terminated

7 enrolled 13 charts

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡